| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/04/2013 | WO2013098140A1 Peritoneal dialysis fluid comprising a gsk-3 inhibitor |
| 07/04/2013 | US20130174288 Antibodies for the treatment of hiv |
| 07/04/2013 | US20130172847 Compositions for Providing Vitamin D Year Round and Uses Thereof |
| 07/04/2013 | US20130172430 Prognosis and treatment of breast cancer |
| 07/04/2013 | US20130172425 Compositions and methods for treating hoof diseases |
| 07/04/2013 | US20130172418 Pharmaceutical composition comprising n-acetyl-l-cysteine or its derivatives for treating anxiety disorder |
| 07/04/2013 | US20130172417 Medium chain peroxycarboxylic acid compositions |
| 07/04/2013 | US20130172383 Treatment of fibrosing disorders |
| 07/04/2013 | US20130172382 Abuse-resistant controlled-release opioid dosage form |
| 07/04/2013 | US20130172373 Quinazoline compounds |
| 07/04/2013 | US20130172372 Ring-fused 4-aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases |
| 07/04/2013 | US20130172368 Methods for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halogenic Acid and A Second Urate-Lowering Agent |
| 07/04/2013 | US20130172360 Derivatives of azaindazole or diazaindazole type as medicament |
| 07/04/2013 | US20130172359 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders |
| 07/04/2013 | US20130172358 Compounds, Formulations, and Methods for Treating or Preventing Inflammatory Skin Disorders |
| 07/04/2013 | US20130172357 Compositions and Methods for Treatment of Glaucoma |
| 07/04/2013 | US20130172356 Combination of egcg or methylated egcg and a pde inhibitor |
| 07/04/2013 | US20130172351 Dihydropyrazoles |
| 07/04/2013 | US20130172349 Inhibitors of phosphatidylinositol 3-kinase |
| 07/04/2013 | US20130172344 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| 07/04/2013 | US20130172337 Imidazo[4,5-c]quinolines as DNA-PK inhibitors |
| 07/04/2013 | US20130172334 Trpv1 antagonists |
| 07/04/2013 | US20130172331 Novel oxazine derivatives and their use in the treatment of disease |
| 07/04/2013 | US20130172330 Chemokine Receptor Modulators |
| 07/04/2013 | US20130172327 Substituted n- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin c |
| 07/04/2013 | US20130172325 Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| 07/04/2013 | US20130172313 Carbapenem Antibacterials with Gram-Negative Activity |
| 07/04/2013 | US20130172311 Substituted heterocyclyl benzyl pyrazoles, and use thereof |
| 07/04/2013 | US20130172304 Pharmaceutical Compositions Comprising Flibanserin and a Further Agent in the Treatment of Sexual Disorders |
| 07/04/2013 | US20130172302 Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof |
| 07/04/2013 | US20130172301 Biphenyl compounds useful as muscarinic receptor antagonists |
| 07/04/2013 | US20130172300 New hormonal composition and its use |
| 07/04/2013 | US20130172299 Combination Therapy for Treatment of Bone and Mineral Disorders for Patients with Impaired Renal Function |
| 07/04/2013 | US20130172275 Inhibiting binding of fgf23 to the binary fgfr-klotho complex for the treatment of hypophosphatemia |
| 07/04/2013 | US20130172259 Modified vitamin k-dependent polypeptides |
| 07/04/2013 | US20130172257 Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| 07/04/2013 | US20130172252 Methods for promoting hair growth |
| 07/04/2013 | US20130172251 Modified ghrelin peptides |
| 07/04/2013 | US20130172249 Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
| 07/04/2013 | US20130172248 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, process for preparation thereof and use thereof as a medicament |
| 07/04/2013 | US20130172240 Methods for treating hcv |
| 07/04/2013 | US20130172239 Solid compositions |
| 07/04/2013 | US20130172238 Method for selective oligonucleotide modification |
| 07/04/2013 | US20130171268 Methods and compositions for treatment of mitochondrial toxicity |
| 07/04/2013 | US20130171223 Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients and supression of crystallization of pharmaceutical active incredients |
| 07/04/2013 | US20130171210 Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications |
| 07/04/2013 | US20130171205 Nanocell Drug Delivery System |
| 07/04/2013 | US20130171201 Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions |
| 07/04/2013 | US20130171193 Therapeutic vaccination against active tuberculosis |
| 07/04/2013 | US20130171187 Glucan-based vaccines |
| 07/04/2013 | US20130171178 Immunogenic Peptides of Xage-1 |
| 07/04/2013 | US20130171162 Compositions and methods for the prevention of oxidative degradation of proteins |
| 07/04/2013 | US20130171161 Method and composition for the treatment of diseases caused by or associated with hiv |
| 07/04/2013 | US20130171157 NOGO Receptor-Mediated Blockade of Axonal Growth |
| 07/04/2013 | US20130171151 Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease |
| 07/04/2013 | US20130171149 Anti-ANGPTL3 Antibodies and Uses Thereof |
| 07/04/2013 | US20130171146 Dual-specific il-1a/ il-1b antibodies |
| 07/04/2013 | US20130171141 Combination of hdac inhibitors with thrombocytopenia drugs |
| 07/04/2013 | US20130171139 Ncam-vase and neurodegeneration |
| 07/04/2013 | US20130171135 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
| 07/04/2013 | US20130171133 Cancer methods |
| 07/04/2013 | US20130171127 Composition for regenerating normal tissue from fibrotic tissue |
| 07/04/2013 | US20130171124 Compositions And Methods Of Treating Head And Neck Cancer |
| 07/04/2013 | US20130171120 Composition for enhancing physical performance |
| 07/04/2013 | US20130171112 Methods for promoting hair growth |
| 07/04/2013 | US20130171103 Methods for treating viral conditions |
| 07/04/2013 | US20130171102 Heterocyclic flaviviridae virus inhibitors |
| 07/04/2013 | US20130171099 Treatment of t-cell mediated immune disorders |
| 07/04/2013 | US20130171098 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors |
| 07/04/2013 | US20130171094 Use of vanadium compounds to accelerate bone healing |
| 07/04/2013 | US20130171091 Nanocell Drug Delivery System |
| 07/04/2013 | US20130171090 Methods of treating hepatic encephalopathy |
| 07/04/2013 | US20130171082 Extract of the above-ground portions of gynandropsis gynandra or cleome gynandra, and cosmetic, dermatological or pharmaceutical compositions including same |
| 07/04/2013 | US20130171063 Antibodies Directed to the Unprocessed Receptor Tyrosine Kinase c-Met |
| 07/04/2013 | US20130171059 Dual variable domain immunoglobulins and uses thereof |
| 07/03/2013 | EP2609933A1 Aqueous composition for ophthalmic administration |
| 07/03/2013 | EP2609928A2 Use of cannabinoids in combination with an anti-psychotic medicament |
| 07/03/2013 | EP2609920A1 Method of treating cancer by a combined therapy of YM-155 with other anticancer agents |
| 07/03/2013 | EP2609064A2 Pharmaceutical compositions comprising poh derivatives |
| 07/03/2013 | EP2608794A1 Methods and compositions for preventing or treating obesity |
| 07/03/2013 | EP2608788A1 Polymorphs of saxagliptin hydrochloride and processes for preparing them |
| 07/03/2013 | CN103183725A A method of detecting protein lysine crotonylation acylation modification and developing affinity reagents |
| 07/03/2013 | CN103182084A Alpha-glucosidase inhibitor |
| 07/03/2013 | CN103181932A Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system |
| 07/03/2013 | CN103181919A Stable ophthalmic formulations |
| 07/03/2013 | CN103181566A Powderous formulations of fat-soluble active ingredients |
| 07/03/2013 | CN102406940B Application of nanoscale flaky carboxymethyl starch sodium in solid dispersion |
| 07/03/2013 | CN102105147B Therapeutic combination comprising an AURORA kinase inhibitor and an antineoplastic agent |
| 07/03/2013 | CN101987200B Compound medicine containing antihypertensive peptide and aldosterone receptor antagonist for curing hypertension |
| 07/03/2013 | CN101445555B Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions |
| 07/02/2013 | US8476454 IDO inhibitors and methods of use |
| 07/02/2013 | US8476416 comprises a dinucleotide analog that includes a non-naturally occurring pyrimidine base; for treating autoimmune disorders, such as autoimmune asthma; allergies |
| 07/02/2013 | US8476280 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
| 07/02/2013 | US8476260 Antitumor agent |
| 07/02/2013 | US8476254 Methods for treating psychosis associated with interferson-α therapy |
| 07/02/2013 | US8476231 Conditioned cell culture medium compositions and methods of use |
| 07/02/2013 | US8475834 Method of improving absorption of vitamin E by a pet animal |
| 07/02/2013 | US8475787 Beneficial effects of bacteriophage treatments |
| 07/02/2013 | US8475780 Ion binding polymers and uses thereof |
| 07/02/2013 | CA2619219C Use of .beta.-1,3 (4)-endoglucanohydrolase, .beta.-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |